Orizuru Therapeutics and Axcelead DDP Collaborate on Drug Discovery Support Services Regarding iPS Cells
Kyoto and Kanagawa, Japan, March 10, 2023 — Orizuru Therapeutics Inc. (“OZTx”) and Axcelead Drug Discovery Partners,...
Teijin and Axcelead to Establish Drug Discovery Research JV
Tokyo, Japan, February 20, 2023 — Teijin Limited and Axcelead, Inc. jointly announced today their basic agreement...
Axcelead DDP Selected as Project Partner for Harvard Business School Immersive Field Course
Axcelead Drug Discovery Partners Inc. (Head Office: Fujisawa, Kanagawa prefecture, CEO: Yoshinori Ikeura, “Axcelead DDP”) was...
Kaken Pharmaceutical and Axcelead DDP Begin Collaboration to Create Innovative New Drugs
Kaken Pharmaceutical Co., Ltd. (“Kaken”, Head Office: Bunkyo-ku, Tokyo; President and Representative Director, Hiroyuki Horiuchi) and Axcelead...
ThinkCyte and Axcelead DDP collaborate to advance novel phenotypic screening methods
Tokyo and Fujisawa, Japan. December 27, 2022: ThinkCyte and Axcelead Drug Discovery Partners (DDP) announced a research...
Axcelead Drug Discovery Partners, Inc. has become a certified provider of spatial transcriptomics technology, Visium, from 10x Genomics
We’re delighted to announce that we have received official certification from 10x Genomics as a Certified Service...